AAAAAA

   
Results: 1-2 |
Results: 2
ASSURING THE OPTIMAL USE OF SEROTONIN ANTAGONIST ANTIEMETICS - THE PROCESS FOR DEVELOPMENT AND IMPLEMENTATION OF INSTITUTIONAL ANTIEMETIC GUIDELINES AT MEMORIAL SLOAN-KETTERING-CANCER-CENTER
Authors: NOLTE MJ BERKERY R PIZZO B BALTZER L GROSSANO D LUCARELLI CD KRIS MG
Citation: Mj. Nolte et al., ASSURING THE OPTIMAL USE OF SEROTONIN ANTAGONIST ANTIEMETICS - THE PROCESS FOR DEVELOPMENT AND IMPLEMENTATION OF INSTITUTIONAL ANTIEMETIC GUIDELINES AT MEMORIAL SLOAN-KETTERING-CANCER-CENTER, Journal of clinical oncology, 16(2), 1998, pp. 771-778
PHASE-II STUDY OF THE COMBINATION OF THE NOVEL BIOREDUCTIVE AGENT, TIRAPAZAMINE, WITH CISPLATIN IN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG-CANCER
Authors: MILLER VA NG KK GRANT SC KINDLER H PIZZO B HEELAN RT VONROEMELING R KRIS MG
Citation: Va. Miller et al., PHASE-II STUDY OF THE COMBINATION OF THE NOVEL BIOREDUCTIVE AGENT, TIRAPAZAMINE, WITH CISPLATIN IN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG-CANCER, Annals of oncology, 8(12), 1997, pp. 1269-1271
Risultati: 1-2 |